Filing Details
- Accession Number:
- 0001415889-24-021452
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-16 16:09:38
- Reporting Period:
- 2024-08-14
- Accepted Time:
- 2024-08-16 16:09:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1370053 | Anaptysbio Inc | ANAB | Pharmaceutical Preparations (2834) | 203828755 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1711462 | F. Paul Lizzul | C/O Anaptysbio, Inc. 10770 Wateridge Circle, Suite 210 San Diego CA 92121 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-08-14 | 2,000 | $18.50 | 13,618 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-08-14 | 2,000 | $40.00 | 11,618 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common | Common | Disposition | 2024-08-14 | 2,000 | $0.00 | 2,000 | $18.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
86,500 | 2030-07-29 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2023.
- The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- In addition to the remaining options to purchase 86,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms.